Page 38 - IJB-9-5

International Journal of Bioprinting 3D bioprinted vascularized tissue models

properties of their native counterparts [72-74] . In this context, Availability of data
incorporating tissue-specific dECMs could lead to the Not applicable.
bioprinting of complex and biomimetic models with more
improved biofunctionality. The success of bioprinted References
models will largely rely on their level of maturity and
sustainable functionality. Future bioprinted vascularized 1. Leung CM, de Haan P, Ronaldson-Bouchard K, et al., 2022, A
models should accommodate all biomimetic aspects, guide to the organ-on-a-chip. Nat Rev Methods Primers, 2(1): 33.
including pre-defined multi-scale vascular organization, https://doi.org/10.1038/s43586-022-00118-6
heterocellular compositions, and coordinated stimulating
factors toward organ-level complexity. 2. Wu Q, Liu J, Wang X, et al., 2020, Organ-on-a-chip: Recent
breakthroughs and future prospects. Biomed Eng Online,
In summary, 3D bioprinting has opened up a promising 19(1): 9.
route to model human biology and diseases in vitro. As a
next-generation research platform, 3D-bioprinted in vitro https://doi.org/10.1186/s12938-020-0752-0
models are now poised to make a significant impact on the 3. Fetah K, Tebon P, Goudie MJ, et al., 2019, The emergence of
clinic to accelerate drug development and serve as living 3D bioprinting in organ-on-chip systems. Prog Biomed Eng,
avatars for personalized medicine. 1(1): 012001.
https://dx.doi.org/10.1088/2516-1091/ab23df
Acknowledgments 4. Yi H-G, Kim H, Kwon J, et al., 2021, Application of 3D
None. bioprinting in the prevention and the therapy for human
diseases. Signal Transduct Target Ther, 6(1): 177.
Funding https://doi.org/10.1038/s41392-021-00566-8
This work was supported by Business for Startup growth 5. Ingber DE, 2022, Human organs-on-chips for disease
and technological development (TIPS Program) funded by modelling, drug development and personalized medicine.
Korea Ministry of SMEs and Startups in 2020 (No. S3032532) Nat Rev Genet, 23(8): 467–491.
and the Bio & Medical Technology Development Program https://doi.org/10.1038/s41576-022-00466-9
of the National Research Foundation (NRF) funded by the 6. Mota C, Camarero-Espinosa S, Baker MB, et al., 2020,
Korea government (MSIT) (No. 2023M3A9G1058216) Bioprinting: From tissue and organ development to in vitro
(Dong-Heon Ha). This work was supported by a National models. Chem Rev, 120(19): 10547–10607.
Research Foundation of Korea (NRF) grant funded by the
Korean government (MSIT) (No. 2020R1C1C1011147) https://doi.org/10.1021/acs.chemrev.9b00789
(Hyungseok Lee). 7. O’Connor C, Brady E, Zheng Y, et al., 2022, Engineering the
multiscale complexity of vascular networks. Nat Rev Mater,
Conflict of interest 7(9): 702–716.

The authors declare no conflict of interest. https://doi.org/10.1038/s41578-022-00447-8
8. Grebenyuk S, Abdel Fattah AR, Kumar M, et al., 2023, Large-
Author contributions scale perfused tissues via synthetic 3D soft microfluidics.
Nat Commun, 14(1): 193.
Conceptualization: Suhun Chae, Hyungseok Lee
Funding acquisition: Dong-Heon Ha, Hyungseok Lee https://doi.org/10.1038/s41467-022-35619-1
Supervision: Hyungseok Lee 9. Fleischer S, Tavakol DN, Vunjak-Novakovic G, 2020, From
Visualization: Suhun Chae arteries to capillaries: Approaches to engineering human
Writing – original draft: Suhun Chae vasculature. Adv Funct Mater, 30(37): 1910811.
Writing – review & editing: Dong-Heon Ha, Hyungseok Lee https://doi.org/10.1002/adfm.201910811

Ethics approval and consent to participate 10. Li S, Jin J, Zhang C, et al., 2023, 3D bioprinting vascular
networks in suspension baths. Appl Mater Today, 30: 101729.
Not applicable.
https://doi.org/10.1016/j.apmt.2022.101729
Consent for publication 11. Seah T, Wong WL, Beh C, 2022, Vascularization strategies
for bioprinting. Mater Today, 70: 638–642.
Not applicable.
https://doi.org/10.1016/j.matpr.2022.10.026

Volume 9 Issue 5 (2023) 30 https://doi.org/10.18063/ijb.748